Kornimate/medical-research-clean huggingface dataset:
superficial endometriosis in magnetic resonance imaging

Conditions: Endometriosis

Summary: the purpose of the study is to determine the correlation between the diagnosis of superficial endometriosis by the 3dt1 sequence on magnetic resonance imaging and the histology obtained by laparoscopy.

this is a prospective, multicenter, non-randomized study evaluating the diagnostic performance of magnetic resonance imaging in superficial endometriosis. the duration of the patient's participation in the study is a maximum of 15 months depending on the length of the screening period and the time between magnetic resonance imaging and laparoscopy. after selection, the investigator will check the patient's eligibility and offer her the study. if she accepts and signs the informed consent form, the patient will have an exploratory pelvic magnetic resonance imaging lasting approximately 15 to 20 minutes, without systematic injection of contrast product. after magnetic resonance imaging, the patient will benefit from a laparoscopy under general anesthesia lasting an average of one hour.

Eligibility criteria:
inclusion criteria : * age ≥ 18 years; * non-menopausal patient; * patient scheduled for exploratory laparoscopy; * patient requiring a preoperative pelvic mri * patient having been informed and having signed an informed consent form. exclusion criteria : * classic contraindications to magnetic resonance imaging; * contraindications to anesthesia for exploratory laparoscopy; * contraindication to surgery following the findings of magnetic resonance imaging results; * patient with endometrioma \> 4 cm; * patient with known deep endometriosis; * patient uncooperative with protocol requirements or unable to attend the center for scheduled visits; * pregnant woman or woman of childbearing age, without effective contraception or breastfeeding; * patient participating in another clinical trial, or during a period of exclusion from another clinical trial; * patient under guardianship, under curatorship or subject to legal protection, persons deprived of liberty by a judicial or administrative decision, persons subject to psychiatric care and admitted to a health or social establishment; * patient not beneficiary of a social security system * patient under state medical aid.
effect of c-peptide on diabetic peripheral neuropathy

Conditions: Diabetes Mellitus, Type 1; Diabetic Polyneuropathy

Summary: the aim of the study is to investigate the effect of c-peptide administration on nerve function in patients with type 1 diabetes and peripheral sensory neuropathy.

it has been observed that c-peptide administration results in an activation of renal tubular and sciatic endoneural na/k-atpase of the rat and stimulation of endothelial nitric oxide synthase. the hypothesis is that c-peptide administration may improve peripheral nerve dysfunction in diabetic neuropathy by increasing nerve blood flow and na/k-atpase activity. the purpose of the trial is to investigate the effect of c-peptide administration on diabetic peripheral sensory neuropathy in patients with type 1 diabetes and diabetic neuropathy in the lower extremities.

Eligibility criteria:
inclusion criteria: * subjects who have a duration of type 1 diabetes of more than 5 yrs * subjects who are c-peptide deficient * subjects who have diabetic distal symmetric neuropathy, according to the criteria defined at the san antonio conference on diabetic neuropathy 1988 * subjects who have measurable action potential in the sural nerves * subjects who have reduced nerve conduction velocity in the sural nerves exclusion criteria: * subjects who have neuropathy or signs of nerve dysfunction which may be a consequence of factors other than type 1 diabetes * subjects who have concomitant medication that may interfere with the peripheral nerve function or measurement thereof * subjects who are transplanted (islet cell, kidney or pancreas)
needs-tailored nurse-led recovery program for community-dwelling people with schizophrenia

Conditions: Schizophrenia; Recovery; Medication Adherence

Summary: meeting people's needs is positively correlated with their recovery. however, recovery services rarely include nurse-led programs tailored to the needs of these people. this study aimed to evaluate the effectiveness of a new needs-tailored recovery program by using a cluster-randomized controlled trial design.

first year, investigators used the pilot study to test the needs tailored recovery program feasibility, acceptability and preliminary usefulness of the needs-tailored nurse-led recovery program. in the second year, based on the findings of the pilot study, a cluster randomized controlled trial was conducted to assess the effectiveness of the needs-tailored nurse-led recovery program in two psychiatric centers in northern taiwan. the treatment group receive the needs-tailored nurse-led recovery program by their home-care nurses over 6 months. the control group receive the usual community psychiatric care only. data were collected before the intervention, after the intervention, and at a follow-up session three months after the end of the intervention period. the outcomes were recovery, needs, hope, empowerment, psychotic symptoms, and medication adherence. the investigators used repeated measures anova tests to examine the effect of the group × time interaction.

Eligibility criteria:
inclusion criteria: * were living in the community and had a diagnosis of schizophrenia based on the diagnostic and statistical manual of mental disorders, fifth edition (dsm-5) * were aged 20-64 years * were able to communicate in mandarin or taiwanese. exclusion criteria: * were living in a community institution such as a recovery home, community rehabilitation center, nursing home, or day hospital * had a neurocognitive disorder, substance abuse disorder, or comorbidity.

Keywords: needs-tailored recovery empowerment hope medication adherence cluster-randomized controlled trial
a study to evaluate safety and immune response of novartis meningococcal acwy conjugate vaccine in adolescents

Conditions: Meningococcal Meningitis; Human Papillomavirus Infection; Pertussis; Tetanus

Summary: this study will evaluate the safety and immune response of the novartis meningococcal acwy conjugate vaccine when administered with tdap and hpv vaccinations to healthy adolescents


Eligibility criteria:
inclusion criteria: * healthy adolescents 11-18 years of age * virgins (both male and female) with no intention of becoming sexually active during the study period * who have been properly vaccinated against diphtheria, tetanus, pertussis exclusion criteria: * who had a previous confirmed or suspected disease caused by n. meningitidis; * who have previously been immunized with a meningococcal vaccine * who have received prior human papillomavirus (hpv) vaccine; * who have any serious acute, chronic or progressive disease * who have epilepsy, any progressive neurological disease or history of guillain-barre syndrome; * who have a known or suspected impairment/alteration of immune function, either congenital or acquired * who are known to have a bleeding diathesis, or any condition that may be associated with a prolonged bleeding time; * who have down's syndrome or other known cytogenic disorders;

Keywords: meningococcal meningitis vaccine adolescents
vision assessment with the quick contrast sensitivity function (qcsf) method in healthy controls and ms

Conditions: Multiple Sclerosis

Summary: victor2 is an observational cohort study over two years and is designed to investigate longitudinal changes of visual impairment in multiple sclerosis (ms). the investigators aim to recruit patients in the relapsing-remitting phase of the disease (n=50) as well as progressive ms patients (n=50). both cohorts will be compared with age and gender matched healthy controls (hc). all participants undergo yearly clinical assessments including standard charts for visual acuity (sloan, snellen), a new computer adaptive test measuring the complete contrast sensitive function (csf), optical coherence tomography and a vision related quality of life questionnaire (nei-vfq). the study aims to validate and extend previous finding from a cross-sectional study which found a better association between csf and nei-vfq than for standard charts. moreover, the study is designed to proof also a better association with anterior visual system integrity as assessed with oct.


Eligibility criteria:
inclusion criteria: inclusion criteria relapsing-remitting ms * relapsing-remitting ms * expanded disability status scale (edss) score between 0 and 6.0 * no other major neurological or psychiatric disorder (such as major depression or schizophrenia) * age 18 - 65 years inclusion criteria progressivems * primary or secondary-progressive ms according to the revised mcdonald criteria * expanded disability status scale (edss) score between 3.0 and 6.0 * no relapse in the last 12 months * no other major neurological or psychiatric disorder (such as major depression or schizophrenia) * age 18 - 65 years exclusion criteria: * cataract and other major ophthalmological diseases (e.g. uveitis, glaucoma) * hyperopia \> 5 dpt, myopia \> -7 dpt, astigmatisms \> 3 dpt * neuromyelitis optica spectrum diseases
a study to learn about the awareness and knowledge that doctors have about the safety and safe use information for androcur and other cyproterone acetate treatments in europe

Conditions: Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea; Hypersexuality in Men; Sexual Deviations in Men; Prostate Cancer

Summary: androcur is a type of treatment called cyproterone acetate (cpa). androcur and other cpa treatments work by blocking a group of male sex hormones called androgens in the body. it can be given to men and women to treat conditions that are caused by higher levels of androgens. cpas, including androcur, are currently available as treatments for doctors to give to patients who have these types of conditions. but, in a study, researchers found that participants had a certain medical problem when they took cpas for a long time. this medical problem was a tumor of the brain or spinal cord that is mostly not malignant and is called meningioma. this eventually led health authorities to change the instructions for how doctors should use cpas to treat patients. this included what health conditions should be treated with cpas, how long patients should receive them, and what dose of cpa should be given. in this study, the researchers want to learn more about how doctors are using cpas to treat patients after the update to the instructions. to answer this research question, they will give to the doctors a web-based questionnaire asking about the advisability or necessity of the treatment (also called "indications of approved use"), the measures to be followed to reduce the risk and how much the doctors knew about the risk of meningioma. the researches will then analyze the answers to the questionnaire. the results will be the percentage of physicians with correct answers for each individual knowledge question from the questionnaire. the study will include information collected from a diverse sample of doctors during approximately 3 months. the doctors must have given cpas as a treatment to at least 1 patient in the last 12 months. there are no required visits or tests in this study.


Eligibility criteria:
inclusion criteria: * licensed and practising dermatologist, endocrinologist, gynaecologist, general practitioners, urologist, oncologist (who treats prostate cancer), or psychiatrist involved in the treatment of hypersexuality/reduction of drive in sexual deviations * prescribed cpa monotherapy to at least one patient in the past 12 months * work in an office or hospital-based setting * electronic acknowledgement of informed consent exclusion criteria: * not applicable

Keywords: cyproterone acetate monotherapies effectiveness of risk minimization measures survey
perfusion parameters and outcome during a standardized deresuscitation strategy with net ultrafiltration: a retrospective cohort study.

Conditions: Fluid Overload; Acute Kidney Injury; Continuous Renal Replacement Therapy

Summary: hemodynamic tolerance of fluid removal during deresuscitation is a cornerstone of the impact on outcome of such a strategy. however, how to define and to predict hemodynamic tolerance to fluid removal remains controversial. the investigators routinely use a standardized deresuscitation protocol in patients with fluid overload and continuous renal replacement therapy combined with monitoring of clinical and biological perfusion parameters. the aim of the study was to describe perfusion during deresuscitation, and to determine whether it is associated with major adverse kidney events at day 30.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years old * acute kidney injury requiring continuous renal replacement therapy * standardized deresuscitation following a routine care protocol exclusion criteria: * chronic hemodialysis * advanced directives to withhold or withdraw life-sustaining treatment, * patient's opposition to the use of his/her personal health data
use of bedside imaging and community health workers for early screening and referral of pre-symptomatic stage b heart failure in the emergency department

Conditions: Heart Diseases

Summary: the goal of this clinical trial is to learn if using point-of-care ultrasound (pocus) can increase participant engagement and changes in behavior among adults with risk factors for pre-symptomatic heart failure presenting to the emergency department. the main questions it aims to answer are: 1. does pocus increase understanding of heart failure and the likelihood to improve diet, exercise, and follow up? 2. does pocus improve diet, exercise, follow up, and self-efficacy at three months post-intervention? researchers will compare an educational intervention with versus without pocus to see if pocus works to improve outcomes. participants will: receive either the educational intervention alone or an educational intervention plus pocus. they will report the difference in their understanding and likelihood to improve diet, exercise, and follow up immediately post-intervention. they will also report changes in diet, exercise, follow up, and self-efficacy at three months post-intervention.


Eligibility criteria:
inclusion criteria: * must be 45 years of age or older * must have high blood pressure, diabetes mellitus, or obesity (body mass index ≥30 kg/m2) exclusion criteria: * symptoms of acute heart failure (difficulty breathing, leg swelling) * history of heart failure * unable to tolerate an ultrasound examination * no access to a phone for follow up

Keywords: pocus ultrasound ultrasonography echocardiography
hemoglobin masimo (pronto 7) and laboratory measurement

Conditions: Emergencies

Summary: the purpose of this study is to compare the hemoglobin results obtained with the masimo pronto 7 and the clinical laboratory.


Eligibility criteria:
inclusion criteria: * emergency unit patients requiring an hemoglobin determination exclusion criteria: * none
cp-481,715 nickel allergy study.

Conditions: Dermatitis, Allergic Contact

Summary: to evaluate the suitability of contact allergy as a method for the evaluation of c-chemokine receptor-1 antagonist.


Eligibility criteria:
inclusion criteria: * a history of nickel allergy confirmed by a visual positive reaction (graded at least ++) to t.r.u.e. test. exclusion criteria: * subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding contact allergic dermatitis or untreated, asymptomatic, seasonal allergies at time of dosing).
thoracic hyperkyphosis and low back pain

Conditions: Low Back Pain

Summary: this study was conducted on forty male patients (15 in the control group and 25 in the study group)) with low back pain hyperkyphosis of the thoracic spine, ages ranged from 20 - 40 years old. the visual analogue scale, the oswestry disability questionnaire, and cobb's angle was assessed for all patients before any intervention and two months post-intervention.

this study was conducted on 40 male patients aged 20 to 40 suffering from lbp. patients were included in the study if they had hyperkyphosis with an x-ray cobb's angle greater than 40 degrees. the visual analogue scale (vas), the oswestry disability questionnaire (odi), and cobb's angle were assessed for all patients before and one month post-intervention. patients who met the inclusion criteria and agreed to participate in this study were randomly assigned to one of the two groups. group 1 (the control group) received the usual care for the lumbar spine which includes tens, ultrasound, and myofascial release for the lumbar spine in addition to a core program including bridge, half bridge and clam shell exercise. group 2 (the study group) received the triple attack protocol which includes a modified p-a mobilization, manipulation, and stabilization program (active and passive) for the thoracic spine in addition to the usual care and the core program for the lumbar spine

Eligibility criteria:
inclusion criteria: * patients who has low back pain due to facet joint arthropathy or discogenic cause confirmrd by mri. chronic spine instability confirmed by clinical tests. sacroiliac joint confirmed by claster of lattelets. hyperkyphosis (\>40 degree measured by cobb's angle) exclusion criteria: * any structural deformity (wedge fracture) or previous spinal surgeries. spinal tumors or fracture or presence of active infection in the lumbar spine. systematic disorder (rheumatoid) cauda equine lesion, the presence of any comorbidities such as hypertension, dm, hyperlipidemia, obesity, and any autoimmune disease, history of patients who suffered from cancer, unexplained weight loss, immunosuppression, prolonged use of steroids, intravenous drug use, urinary tract infection, pain that is increased or unrelieved by rest, fever, significant trauma related to age, bladder or bowel incontinence, urinary retention (with overflow incontinence), saddle anesthesia, loss of anal sphincter tone, major motor weakness in lower extremities, fever, and vertebral tenderness.

Keywords: hyperkyphosis cobb's angle
study of netarsudil ophthalmic solution in japanese/japanese-american subjects with open-angle glaucoma or ocular hypertension

Conditions: Primary Open Angle Glaucoma or Ocular Hypertension

Summary: to test the safety and effectiveness of ar-13324 0.02% and 0.04% ophthalmic solution relative to placebo in japanese/japanese-american subjects with open-angle glaucoma or ocular hypertension in us.


Eligibility criteria:
inclusion criteria: 1. must be 18 years or older 2. be of japanese ethnicity within the 2nd generation defined as (a) 1st generation born in japan, immigrated to us and (b) 2nd generation - parents are 1st generation and patient was born in us as an american citizen 3. diagnosis of open-angle glaucoma or ocular hypertension in both eyes 4. medicated intraocular pressure \>/= 15 mmhg and \< 30 mmhg in both eyes at screening 5. oag eyes - unmedicated iop \>/= 15 mmhg and \< 35 mmhg at 2 qualification visits at 08:00, 10:00 and 16:00 6. oht eyes - unmedicated iop \>/= 22 mmhg and \< 35mmhg at 08:00, 10:00 and 16:00 7. best corrected visual acuity + 1.0 logmar or better by etdrs in each eye 8. able to give signed informed consent and follow instructions exclusion criteria: 1. clinically significant ocular disease 2. pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure glaucoma or narrow angles 3. intraocular pressure \>/=35 mmhg in either eye 4. ocular hyperemia score of moderate (+2) at qualification visit #2 5. previous glaucoma intraocular surgery 6. refractive surgery in either eye 7. ocular injury within 6 months prior to screening or ocular surgery or non-refractive laser treatment within 3 months prior to screening 8. recent or current ocular infection or inflammation in either eye 9. use of ocular medication in either eye of any kind within 30 days of screening and throughout the study 10. mean central corneal thickness \> 620 µm in either eye 11. any abnormality preventing reliable applanation tonometry of either eye 12. known hypersensitivity to benzalkonium chloride or excipients of netarsudil ophthalmic solution 13. clinically significant abnormalities in screening lab tests 14. clinically significant systemic disease that might interfere with the study 15. participated in any investigational study within 30 days prior to screening 16. systemic medication that could have a substantial effect on iop within 30 days prior to screening or anticipated during the study 17. women of child-bearing potential who are pregnant, nursing, planning a pregnancy or not using a medically acceptable form of birth control
exploratory study of drug sensitivity prediction software (ircr-dress) with patient-derived tumor cells of metastatic gastric cancer

Conditions: Stomach Neoplasms

Summary: 1. metastatic gastric cancer patients who failed standard treatment will be enrolled in this study. 2. after consent form, patient-derived cancer cell will be collected and tested with 3 kinds of drugs (sunitinib, gefitinib, imatinib). 3. drug sensitivity prediction software (ircr-dress) will present level of sensitivity and patients will be treated with sensitive drugs. 4. patients will be evaluated every 6 weeks.


Eligibility criteria:
inclusion criteria: * age\>-20 * metastatic gastric cancer * life expectancy \>-3 months * ascites and pleural effusion that can be drained * ecog 0-2 * proper organ function * patients who will be enrolled in sunitinib, gefitinib, imatinib clinical trial exclusion criteria: * hbeag, hcv, hiv (+) * active infection * uncontrolled systemic disease
efficacy, safety and tolerability of neramexane in comparison to placebo in patients with subjective tinnitus

Conditions: Subjective Tinnitus

Summary: the purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of subjective tinnitus in comparison to placebo.


Eligibility criteria:
inclusion criteria: * patients aged 18 to 75 years with a clinical diagnosis of first onset, persistent (i.e. tinnitus sghould never be absent for \>24 hours in a row), subjective, uni-or bilateral tinntius present for at least 3 months but not more than 12 months. exclusion criteria: * clinical diagnosis of intermittent or pulsatile tinnitus * patients who have tinnitus as a concomitant symptom of an otological/neurological disease(such as otitis media, meniére´s disease, otosclerosis, etc.)